Analysis of the application value of HPV mRNA and DNA detection in early screening of cervical lesions.

Aim: At present, COBAS human papillomavirus (HPV) and Aptima HPV screening are widely used to detect HPV infection. In this study, we compared and analyzed the positive rates of DNA and mRNA (n = 10,128 women). Methods: After HPV screening, colposcopy was performed. Subsequently, pathological analysis was conducted on the screening results. Results: In Aptima HPV 16 group, the proportion of pathological lesions ≥CIN2 was 32.69%, while in COBAS HPV group, it was 24.18% (p < 0.05). Aptima HPV other risk types and COBAS HPV other risk types, the proportion of cases ≥CIN2 was 12.42 and 5.79%, respectively (p < 0.001). Conclusion: The results illustrated that the Aptima HPV test detects more accurately clinically relevant lesions than the COBAS test. The aim of this study was to evaluate the analysis of the application value of HPV based on RNA and DNA detection in early screening of cervical lesions. In the Aptima HPV 16 group, the proportion of pathological lesions ≥CIN2 level was 32.69%, while in the COBAS HPV group, this proportion was 24.18% (Chi-square test, χ² = 6.135; p < 0.05). There was no difference in pathological test results (≥CIN2) level between Aptima HPV 18/45 and COBAS HPV 18 positive cases. Aptima HPV other risk types and COBAS HPV other risk types, the proportion of cases with ≥CIN2 level was 12.42 and 5.79%, respectively (Chi-square test, χ² = 35.68; p < 0.001). Aptima HPV has better accuracy in early screening of cervical cancer. [ABSTRACT FROM AUTHOR]